
    
      This is a single dose, single period, multiple administration, open-labeled trial in one
      investigation center.

      The screening examination will be completed from Day -14 to Day -2 before investigational
      medicinal product (IMP) administration. The subjects will be hospitalized on Day -1. From Day
      1 (the next day), the subjects will receive probucol twice daily (BID). for 14 consecutive
      days. On Day 18, the subjects can be discharged after the safety evaluation. The follow-up
      visit will occur on Day 6, 9, 12, 15, 19, 27 (totally 41 days) after the final dosing day.
    
  